open access Feb 13, 2018: The Yet Unrealized Promise of Ovarian Cancer Screening

The Yet Unrealized Promise of Ovarian Cancer Screening

 

References

1.

US Preventive Services Task Force.  Screening for ovarian cancer: US Preventive Services Task Force recommendation statement  [published February 13, 2018].  JAMA. doi:10.1001/jama.2017.21926Google Scholar

2.

Henderson  JT, Webber  EM, Sawaya  GF.  Screening for ovarian cancer: updated evidence report and systematic review for the US Preventive Services Task Force  [published February 13, 2018].  JAMA. doi:10.1001/jama.2017.21421Google Scholar

3.

Jacobs  IJ, Menon  U, Ryan  A,  et al.  Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).  Lancet. 2016;387(10022):945-956.PubMedGoogle ScholarCrossref

4.

Buys  SS, Partridge  E, Black  A,  et al; PLCO Project Team.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial.  JAMA. 2011;305(22):2295-2303.PubMedGoogle ScholarCrossref

5.

Jacobs  IJ, Skates  SJ, MacDonald  N,  et al.  Screening for ovarian cancer: a pilot randomised controlled trial.  Lancet. 1999;353(9160):1207-1210.PubMedGoogle ScholarCrossref

6.

Barrett  J, Jenkins  V, Farewell  V,  et al; UKCTOCS trialists.  Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS).  BJOG. 2014;121(9):1071-1079.PubMedGoogle ScholarCrossref

7.

American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice; Society of Gynecologic Oncology. ACOG Committee opinion No. 716, September 2017. https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/The-Role-of-the-Obstetrician-Gynecologist-in-the-Early-Detection-of-Epithelial-Ovarian-Cancer-in. Accessed January 22, 2018.

8.

Marchetti  C, De Felice  F, Palaia  I,  et al.  Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all-cause mortality in BRCA 1 and BRCA 2 mutation carriers.  BMC Womens Health. 2014;14:150.PubMedGoogle ScholarCrossref

9.

Rosenthal  AN, Fraser  LSM, Philpott  S,  et al; United Kingdom Familial Ovarian Cancer Screening Study collaborators.  Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the UK Familial Ovarian Cancer Screening Study.  J Clin Oncol. 2017;35(13):1411-1420.PubMedGoogle ScholarCrossref

10.

Skates  SJ, Greene  MH, Buys  SS,  et al.  Early detection of ovarian cancer using the Risk of Ovarian Cancer Algorithm with frequent CA125 testing in women at increased familial risk.  Clin Cancer Res. 2017;23(14):3628-3637.PubMedGoogle ScholarCrossref

11.

Karlan  BY, Thorpe  J, Watabayashi  K,  et al.  Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.  Cancer Epidemiol Biomarkers Prev. 2014;23(7):1383-1393.PubMedGoogle ScholarCrossref

12.

Menon  U, McGuire  AJ, Raikou  M,  et al.  The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).  Br J Cancer. 2017;117(5):619-627.PubMedGoogle ScholarCrossref

13.

Sieh  W, Salvador  S, McGuire  V,  et al; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium.  Tubal ligation and risk of ovarian cancer subtypes.  Int J Epidemiol. 2013;42(2):579-589.PubMedGoogle ScholarCrossref

14.

Garcia  C, Martin  M, Tucker  LY,  et al.  Experience with opportunistic salpingectomy in a large, community-based health system in the United States.  Obstet Gynecol. 2016;128(2):277-283.PubMedGoogle ScholarCrossref

15.

Powell  CB, Swisher  EM, Cass  I,  et al.  Long-term follow-up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.  Gynecol Oncol. 2013;129(2):364-371.PubMedGoogle ScholarCrossref

16.

Labidi-Galy  SI, Papp  E, Hallberg  D,  et al.  High grade serous ovarian carcinomas originate in the fallopian tube.  Nat Commun. 2017;8(1):1093.PubMedGoogle ScholarCrossref

You May Also Like

• Research
  Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
  February 1, 2018
• Research
  Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction
  January 18, 2018
• Opinion
  Routine Cancer Antigen 125 Surveillance—The Fatal Attraction of Testing
  November 1, 2016

You May Also Like

• Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
  JAMA
  Research
  February 13, 2018
• Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement
  JAMA
  Research
  February 13, 2018
• Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
  JAMA Oncology
  Research
  February 1, 2018